This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/19/2024
Johan Tant
Head of Investor Relations
Then I say welcome to today's presentation from Modus Therapeutics, which has presented its part-time report for the third quarter of 2024. And with me to comment on it I have, as usual, the company's CEO, John Öd. John, we are both a bit crass today. You can hear my voice here and it may disappear, so I have a reservation to get through this, but otherwise you take over, quite simply.
John Öd
CEO
Yes, in that regard, my voice holds. As I said, we both have to lead each other, quite simply.
Johan Tant
Head of Investor Relations
But please comment briefly on the quarter. There are several milestones that have been achieved. I thought the most interesting milestone is the CKD study that is now approved in Italy. I thought we could start there.
You're reading a preview of the MODTX.ST Q3 2024 earnings call.
Free account.
Disclaimer